ArticleRNA (New York, N.Y.)2001
A selection system for identifying accessible sites in target RNAs.
Article in RNA (New York, N.Y.), 2001. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Variables and strategies in development of therapeutic post-transcriptional gene silencing agents.Journal of ophthalmology · 2011Article
- MicroRNAs align with accessible sites in target mRNAs.Journal of cellular biochemistry · 2010Article
- Bottlenecks in development of retinal therapeutic post-transcriptional gene silencing agents.Vision research · 2008Review
- Systemic targeting inhibitor of kappaB kinase inhibits melanoma tumor growth.Cancer research · 2007Article
- Selection of optimal antisense accessible sites of survivin and its application in treatment of gastric cancer.World journal of gastroenterology · 2005Article
- In vitro selection, characterization, and application of deoxyribozymes that cleave RNA.Nucleic acids research · 2005Review
- Inhibition of papilloma progression by antisense oligonucleotides targeted to HPV11 E6/E7 RNA.Gene therapy · 2004Article
- E6AP gene suppression and characterization with in vitro selected hammerhead ribozymes.Cancer gene therapy · 2003Article
- Selection of antisense oligodeoxynucleotides against glutathione S-transferase Mu.RNA (New York, N.Y.) · 2002Article
- Development and comparison of procedures for the selection of delta ribozyme cleavage sites within the hepatitis B virus.Nucleic acids research · 2002Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Although ribozymes offer tremendous potential for posttranscriptionally controlling expression of targeted genes, their utility is often limited by the accessibility of the targeted regions within the RNA transcripts. Here we describe a method that identifies RNA regions that are accessible to oligonucleotides. Based on this selection protocol, we show that construction of hammerhead ribozymes targeted to the identified regions results in catalytic activities that are consistently and substantially greater than those of ribozymes designed on the basis of computer modeling. Identification of accessible sites should also be widely applicable to design of antisense oligonucleotides and DNAzymes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.